Beata Bode
Overview
Explore the profile of Beata Bode including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
618
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mattmann A, Glanzmann C, Fuchs B, Bode B, Studer G
Adv Radiat Oncol
. 2024 Sep;
9(10):101562.
PMID: 39314903
Purpose: Normofractionated preoperative radiation therapy (nRT) with 50 Gy applied in 25 fractions represents the most widely used radiation therapy (RT) regimen in combined local treatment of soft tissue sarcomas...
2.
Heesen P, Schelling G, Birbaumer M, Jager R, Bode B, Studer G, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061155
This manuscript examines the synergistic potential of prospective real-world/time data/evidence (RWTD/E) and randomized controlled trials (RCTs) to enrich healthcare research and operational insights, with a particular focus on its impact...
3.
Fuchs B, Bode B, Heesen P, Kopf B, Michelitsch C, Odermatt M, et al.
Swiss Med Wkly
. 2024 Apr;
154:3473.
PMID: 38579301
No abstract available.
4.
Svantesson T, van Oudenaarde K, Fuchs B, Bode B, Vogetseder A
Arch Clin Cases
. 2023 Oct;
10(3):142-145.
PMID: 37809034
Xanthogranulomatous epithelial tumor (XGET) is an extremely rare and recently described mesenchymal neoplasm characterized by a distinctive histological appearance and clinical presentation. This case report describes a unique case of...
5.
Mosku N, Heesen P, Christen S, Scaglioni M, Bode B, Studer G, et al.
Diagnostics (Basel)
. 2023 Mar;
13(6).
PMID: 36980513
Patient-based health related quality of life (HRQoL) measurements are associated with an improvement in quality of care and outcomes. For a complex disease such as sarcoma, there is no disease-specific...
6.
Heesen P, Studer G, Bode B, Windegger H, Staeheli B, Aliu P, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612043
Sarcomas represent a large group of rare to very rare diseases, requiring complex management with a transdisciplinary approach. Overall progress has been hampered because of discipline, institution and network fragmentation,...
7.
Palm C, Connolly C, Masser R, Padberg Sgier B, Karamitopoulou E, Simon Q, et al.
Diagnostics (Basel)
. 2023 Jan;
13(1).
PMID: 36611460
The expression of human epidermal growth factor receptor 2 (HER2) protein or gene transcripts is critical for therapeutic decision making in breast cancer. We examined the performance of a digitalized...
8.
Blum V, Andrei V, Ameline B, Hofer S, Fuchs B, Strobel K, et al.
Front Oncol
. 2022 Dec;
12:1086677.
PMID: 36578930
Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment....
9.
Mosku N, Heesen P, Studer G, Bode B, Spataro V, Klass N, et al.
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406402
The ratio of malignancy in suspicious soft tissue and bone neoplasms (RMST) has not been often addressed in the literature. However, this value is important to understand whether biopsies are...
10.
Fuchs B, Studer G, Bode B, Wellauer H, Frei A, Theus C, et al.
Swiss Med Wkly
. 2021 Dec;
151:w30047.
PMID: 34964578
The urgent need to restructure healthcare delivery to address rising costs has been recognised. Value-based health care aims to deliver high and rising value for the patient by addressing unmet...